ARDEA - Entering the Pivotal Phase
MP Advisors, September 2011
After a long wait, Ardea (RDEA) reached an agreement with the FDA on the proposed PhIII development plans for Lesinurad (RDEA594, Urate Transporter regulator, Gout, PhIII) and expects to initiate the trials by 4Q11. There is a major unmet medical need for a better treatment option for the majority of gout pts. How will Lesinurad target the WW gout market? Management plans on the development/partnering etc. of Lesinurad is discussed in the report released on 12th September, 2011 on RDEA titled “Entering the Pivotal Phase”
- Ardea
- Allopurinol
- BAY 86-9766
- Febuxostat
- Gout
- Hyperuricemia
- Lesinurad
- Refractory Gout
- RDEA
- Uloric
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network